News - Pharmaceuticals
Astellas engages male MPs on menopause allyship amid delays in PBS funding for therapy

Coinciding with Menopause Awareness Month, Astellas Pharma Australia has brought policymakers, patient advocates and employees together to highlight menopause as both a significant women’s health issue and an increasingly important workplace consideration.
Up to 80% of women experience vasomotor symptoms (VMS), commonly referred to as hot flushes and night sweats, during the menopausal transition. For most people, VMS lasts for around 7.4 years.
Astellas’ non-hormonal treatment, Veoza (fezolinetant), received Therapeutic Goods Administration (TGA) approval in February 2024 for the treatment of moderate to severe VMS associated with menopause. However, despite the Pharmaceutical Benefits Advisory Committee (PBAC) recommending reimbursement following a resubmission at its November 2025 meeting, the treatment is not yet funded under the Pharmaceutical Benefits Scheme (PBS). The committee requested a price reduction and a risk-sharing arrangement as part of its recommendation. In the meantime, Veoza costs approximately $80 per month on a private prescription.
Breast Cancer Network Australia (BCNA) has supported funding for Veoza, recognising that VMS can be especially distressing for women who have undergone treatment for hormone-sensitive breast cancer and are unable to use hormone replacement therapy (HRT).
“My experience using Veoza has been very positive. It has stopped hot flushes that would surge through my body and wake me up multiple times in the night. From a mental health perspective Veoza has helped me hugely. It has allowed me to sleep and to have energy raising my children,” said BCNA Consumer Julia.
Hosted at Astellas’ Macquarie Park office, the event welcomed Jerome Laxale MP, Member for Bennelong; Zhi Soon MP, Member for Banks; and Dr Gordon Reid MP, Member for Robertson. The focus on male MPs reflected the important role allies can play in making menopause easier to discuss, challenging stigma and supporting practical change in workplaces and communities.
An immersive MenoVest experience, delivered by Over The Bloody Moon, further demonstrated the physical effects of symptoms. The vests simulate the sudden heat associated with a hot flush, offering participants a tangible insight into how these episodes can affect comfort, concentration and daily activities.
Guillaume Pfeiffer, General Manager, Astellas Pharma Australia, said “Menopause can have a significant impact on daily life and women’s experience in the workplace. Bringing policymakers closer to lived experience helps build understanding of why menopause matters – not only as a health issue, but for workplaces and communities.”
“By creating space for informed and empathetic conversations, we hope to help normalise menopause, strengthen allyship and keep women ’s needs visible in discussions about health and the workplace,” he added.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More